TY - JOUR AU - Lemere, C. A. PY - 2013 DA - 2013// TI - Immunotherapy for Alzheimer’s disease: hoops and hurdles JO - Mol Neurodegener. VL - 8 UR - https://doi.org/10.1186/1750-1326-8-36 DO - 10.1186/1750-1326-8-36 ID - Lemere2013 ER - TY - JOUR AU - Tayeb, H. O. AU - Murray, E. D. AU - Price, B. H. AU - Tarazi, F. I. PY - 2013 DA - 2013// TI - Bapineuzumab and solanezumab for Alzheimer’s disease: is the ‘amyloid cascade hypothesis’ still alive? JO - Expert Opin Biol Ther. VL - 13 UR - https://doi.org/10.1517/14712598.2013.789856 DO - 10.1517/14712598.2013.789856 ID - Tayeb2013 ER - TY - JOUR AU - Salloway, S. AU - Sperling, R. AU - Fox, N. C. AU - Blennow, K. AU - Klunk, W. AU - Raskind, M. PY - 2014 DA - 2014// TI - Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease JO - N Engl J Med. VL - 370 UR - https://doi.org/10.1056/NEJMoa1304839 DO - 10.1056/NEJMoa1304839 ID - Salloway2014 ER - TY - JOUR AU - Moreth, J. AU - Mavoungou, C. AU - Schindowski, K. PY - 2013 DA - 2013// TI - Passive anti-amyloid immunotherapy in Alzheimer’s disease: what are the most promising targets? JO - Immun Ageing. VL - 10 UR - https://doi.org/10.1186/1742-4933-10-18 DO - 10.1186/1742-4933-10-18 ID - Moreth2013 ER - TY - JOUR AU - Blennow, K. AU - Zetterberg, H. AU - Rinne, J. O. AU - Salloway, S. AU - Wei, J. AU - Black, R. PY - 2012 DA - 2012// TI - Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease JO - Arch Neurol. VL - 69 UR - https://doi.org/10.1001/archneurol.2012.90 DO - 10.1001/archneurol.2012.90 ID - Blennow2012 ER - TY - JOUR AU - Rinne, J. O. AU - Brooks, D. J. AU - Rossor, M. N. AU - Fox, N. C. AU - Bullock, R. AU - Klunk, W. E. PY - 2010 DA - 2010// TI - 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study JO - Lancet Neurol. VL - 9 UR - https://doi.org/10.1016/S1474-4422(10)70043-0 DO - 10.1016/S1474-4422(10)70043-0 ID - Rinne2010 ER - TY - JOUR AU - Salloway, S. AU - Sperling, R. AU - Gilman, S. AU - Fox, N. C. AU - Blennow, K. AU - Raskind, M. PY - 2009 DA - 2009// TI - A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease JO - Neurology. VL - 73 UR - https://doi.org/10.1212/WNL.0b013e3181c67808 DO - 10.1212/WNL.0b013e3181c67808 ID - Salloway2009 ER - TY - JOUR AU - Blennow, K. AU - Hampel, H. AU - Zetterberg, H. PY - 2014 DA - 2014// TI - Biomarkers in amyloid-β immunotherapy trials in Alzheimer’s disease JO - Neuropsychopharmacology. VL - 39 UR - https://doi.org/10.1038/npp.2013.154 DO - 10.1038/npp.2013.154 ID - Blennow2014 ER - TY - JOUR AU - Doody, R. S. AU - Thomas, R. G. AU - Farlow, M. AU - Iwatsubo, T. AU - Vellas, B. AU - Joffe, S. PY - 2014 DA - 2014// TI - Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease JO - N Engl J Med. VL - 370 UR - https://doi.org/10.1056/NEJMoa1312889 DO - 10.1056/NEJMoa1312889 ID - Doody2014 ER - TY - JOUR AU - Panza, F. AU - Solfrizzi, V. AU - Imbimbo, B. P. AU - Giannini, M. AU - Santamato, A. AU - Seripa, D. PY - 2014 DA - 2014// TI - Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease JO - Expert Rev Neurother. VL - 14 UR - https://doi.org/10.1586/14737175.2014.945522 DO - 10.1586/14737175.2014.945522 ID - Panza2014 ER - TY - JOUR AU - Liu, E. AU - Schmidt, M. E. AU - Margolin, R. AU - Sperling, R. AU - Koeppe, R. AU - Mason, N. S. PY - 2015 DA - 2015// TI - Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials JO - Neurology. VL - 85 UR - https://doi.org/10.1212/WNL.0000000000001877 DO - 10.1212/WNL.0000000000001877 ID - Liu2015 ER - TY - JOUR AU - Sperling, R. A. AU - Jack, C. R. AU - Black, S. E. AU - Frosch, M. P. AU - Greenberg, S. M. AU - Hyman, B. T. PY - 2011 DA - 2011// TI - Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup JO - Alzheimers Dement. VL - 7 UR - https://doi.org/10.1016/j.jalz.2011.05.2351 DO - 10.1016/j.jalz.2011.05.2351 ID - Sperling2011 ER -